Tucson, AZ, February 5th 2024 — SynCardia Systems, LLC., a Picard Medical Company, proudly announces that the U.S. Patent and Trademark Office (USPTO) has allowed claims of its groundbreaking patent application “Next Generation Total Artificial Heart” covering next generation total artificial heart designs.
The application describes novel technology aimed at eliminating external drive mechanisms by fully integrating the pumping mechanism within the implanted artificial heart ventricle. This new design represents a significant leap forward towards achieving a fully implantable system.
“We are thrilled to share the news of our latest patent application for the next generation of total artificial hearts. This represents a significant step forward in our commitment to advancing the development of a fully implantable total artificial heart”, commented Patrick NJ Schnegelsberg, CEO. “The technology outlined in this patent has the potential to benefit over 3,000 advanced heart failure patients in the US, as well as patients in Europe, Asia and elsewhere, needing a heart transplant. I congratulate Matt Schuster, the inventor, and our COO for reaching this milestone.”
SynCardia Systems, LLC. is a leader in the development of total artificial hearts. The Company markets and sells the SynCardia Total Artificial Heart, which is the only US Food and Drug Administration (FDA) and Health Canada approved artificial heart. As of last year, the Company has implanted 2,080 SynCardia Total Artificial Hearts, including over 100 of the 50cc SynCardia Total Artificial Heart designed for smaller patients.
“We look forward to continuing our efforts to bring innovative solutions to professionals and consumers alike,” commented Matt Schuster, COO and inventor of the technology.
About SynCardia Systems, LLC
Headquartered in Tucson, Ariz., SynCardia manufactures the world’s only commercially approved total artificial heart. In clinical use for more than 35 years and with more than 1,800 implants, the SynCardia Total Artificial Heart (TAH) is the most widely used and extensively studied TAH in the world. By partnering with, training and supporting healthcare teams at more than 140 transplant hospitals and heart failure programs in more than 20 countries, SynCardia helps create better outcomes for critically ill adults and adolescents whose best chance at survival is total heart replacement. When a donor heart isn’t an available option, SynCardia provides a new heart without the wait for patients with end-stage heart failure affecting both sides of the heart (biventricular failure). https://www.syncardia.com/
SynCardia Systems, LLC – a Picard Medical Company
The SynCardia Total Artificial Heart (TAH-t) is a treatment option for cardiac transplant- eligible patients at risk of imminent death from biventricular failure.
Medical Advice Disclaimer: The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or a qualified health care provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of information you have read on this website.
© SynCardia Systems, LLC | All rights reserved.
Republished with permission
Source: https://www.syncardia.com/download/syncardia_pressrelease_240205.pdf